Type 1 diabetes is one of the most studied yet least understood autoimmune conditions in the world, and a major new study is bringing researchers closer to understanding what triggers it. Scientists from the University of Turku and Tampere University in Finland have confirmed a significant link between chronic enteroviral infections and the onset of type 1 diabetes, shedding new light on how viral infections may destroy the insulin producing beta cells of the pancreas.
Finland has the highest rate of type 1 diabetes in the world, making it a unique and important setting for research into the condition’s environmental and viral triggers.
What Is Type 1 Diabetes and Why Does the Cause Matter?
Type 1 diabetes is an autoimmune disorder in which the immune system destroys the pancreatic beta cells responsible for producing insulin. Without insulin, the body cannot regulate blood sugar, leading to a lifelong dependence on insulin therapy and a significantly elevated risk of serious complications including cardiovascular disease, kidney damage, vision loss, and nerve damage.
Unlike type 2 diabetes, which is strongly associated with lifestyle factors, type 1 diabetes has a strong genetic component but is also believed to be triggered by environmental factors, particularly viral infections. Identifying the specific viral mechanisms that initiate beta cell destruction is critical to developing prevention strategies and new therapeutic targets.
Enteroviruses have long been suspected as a key trigger. This new research adds important molecular evidence to that hypothesis.
How the Study Was Conducted
The research was led by Academy Professor Riitta Lahesmaa of the Turku Bioscience Centre and Professor Heikki Hyoty of Tampere University. The team used advanced proteomic methods to measure how chronic enteroviral infection influences the expression and secretion of thousands of different proteins in cellular models of pancreatic enteroviral infection.
Proteomics, the large scale study of proteins produced by a cell or organism, allows researchers to capture a comprehensive picture of how a biological system responds to an infection. By analyzing protein changes at this scale, the team was able to identify specific molecular pathways disrupted by chronic enteroviral infection in pancreatic cells over a period of almost one year.
Key Findings: What Chronic Infection Does to Pancreatic Cells
After persisting for nearly a year, chronic enteroviral infections significantly modified the cellular expression of numerous proteins critical to basic cellular functions. Among the most affected were proteins involved in regulating energy metabolism, a fundamental process that beta cells depend on to produce and secrete insulin effectively.
The infections also caused measurable alterations in the secretion of several proteins. Levels of proteins involved in the regulated secretory pathway, the mechanism beta cells use to release hormones including insulin, decreased substantially in the presence of chronic infection.
“The levels of proteins in the regulated secretory pathway participating in the secretion of hormones such as insulin in the beta cells decreased with the chronic infection. The infections also clearly affected the levels of other proteins that are involved in the function and survival of beta cells,” said Dr. Niina Lietzén from the Turku Bioscience Centre.
Two Virus Strains, Two Different Responses
One of the most important findings from the study was that chronic infections developed using two different enterovirus strains triggered partly very different cellular responses. Major differences in immune response activation were observed between the two models, indicating that individual virus strains have distinct abilities to manipulate cellular defense systems.
This finding has significant implications for both disease understanding and drug development. If different enterovirus strains trigger different immune and metabolic responses in beta cells, it may explain why type 1 diabetes onset varies so widely among individuals exposed to similar viral environments, and why some individuals progress to full beta cell destruction while others do not.
“This indicates that the viruses have different kinds of abilities to manipulate the cellular defense systems,” said Professor Hyoty.
What This Means for Type 1 Diabetes Research and Clinical Trials
The confirmation that chronic enteroviral infections broadly alter pancreatic cellular functions and reduce insulin secretion capacity strengthens the scientific case for targeting enteroviruses as part of a type 1 diabetes prevention or intervention strategy. This could include antiviral therapies, enterovirus vaccines, or immune-modulating treatments designed to protect beta cells during early viral infection.
Each of these approaches will require rigorous clinical trial evaluation across multiple phases. Research sites with experience enrolling patients with autoimmune and metabolic conditions, as well as access to diverse pediatric and adult populations, will be essential to advancing this work.
FOMAT Medical Research supports clinical trials in endocrinology and metabolic conditions, including studies related to diabetes and pancreatic disease, through our national network of community-based investigators. If you are a Sponsor or CRO developing therapies for type 1 diabetes or related conditions, contact our team to learn how FOMAT can support your next study. You can also explore our endocrinology and metabolic capabilities to learn more about our experience in this therapeutic area.
Source: University of Turku